Bristol-Myers Squibb Company (BMY) announced that the U.S. Food and Drug Administration approved YERVOY 3 mg/kg for the treatment of patients with unresectable or metastatic melanoma.
Bristol-Myers Squibb has agreed with the FDA to conduct a post-marketing study comparing the safety and efficacy of the 3 mg/kg dose vs. an investigational 10 mg/kg dose in patients with unresectable or metastatic melanoma.
The company expects to begin shipping YERVOY within weeks of today's FDA approval.
For comments and feedback: editorial@rttnews.com